Community Epidemiologist

James K. Cunningham, PhD
Phone: 520–615–5080
jkcunnin [at] email.arizona.edu

Reports

1. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs (2012)
Callaghan, R. C., Cunningham, J. K., Sykes, J., & Kish, S. J. (2012). Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug and alcohol dependence, 120(1-3), 35-40.

2. Methamphetamine use and schizophrenia: a population-based cohort study in California (2012)
Callaghan, R. C., Cunningham, J. K., Allebeck, P., Arenovich, T., Sajeev, G., Remington, G., ... & Kish, S. J. (2012). Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry, 169(4), 389-396.

3. Impacts of federal precursor chemical regulations on methamphetamine arrests (2005)
Cunningham, J. K., & Liu, L. M. (2005). Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction, 100(4), 479-488.

4. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine‐related hospital admissions (2003)
Cunningham, J. K., & Liu, L. M. (2003). Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine‐related hospital admissions. Addiction, 98(9), 1229-1237.